CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders, Financial Terms Undisclosed
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders, Financial Terms Undisclosed
Centogene N.V. (NASDAQ:CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the extension of an ongoing partnership with Takeda (NYSE:TAK) to diagnose patients with Lysosomal Storage Disorders (LSDs).
Centogene N.V.（納斯達克股票代碼：CNTG）是爲罕見和神經退行性疾病提供數據驅動答案的重要生命科學合作伙伴，今天宣佈延長與武田（紐約證券交易所代碼：TAK）在診斷溶酶體貯積症（LSD）患者方面的持續合作關係。
Under the renewed agreement, CENTOGENE will continue to provide Takeda with access to diagnostic testing for patients around the world. The agreement was established to enhance patient access to rapid and reliable diagnostics for LSDs, including Fabry disease, Gaucher disease, and Hunter syndrome.
根據續訂的協議，CENTOGENE將繼續爲武田提供全球患者獲得診斷測試的機會。該協議旨在增加患者獲得包括法布里病、高徹病和亨特綜合徵在內的LSD的快速可靠診斷的機會。